These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34242713)

  • 21. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
    Hu Y; Paris S; Sahoo N; Bertolet G; Wang Q; Wang Q; Barsoumian HB; Da Silva J; Huang A; Doss DJ; Pollock DP; Hsu E; Selene N; Leyton CSK; Voss TA; Masrorpour F; Ganjoo S; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
    JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37345658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
    Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
    J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
    Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
    Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
    Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
    J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
    Barsoumian HB; He K; Hsu E; Bertolet G; Sezen D; Hu Y; Cortez MA; Welsh JW
    Res Sq; 2023 Feb; ():. PubMed ID: 36824846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
    Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
    Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
    Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
    Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models.
    Zhang P; Marill J; Darmon A; Mohamed Anesary N; Lu B; Paris S
    Int J Nanomedicine; 2021; 16():2761-2773. PubMed ID: 33880022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody.
    Tej GNVC; Neogi K; Nayak PK
    Int Immunopharmacol; 2019 Dec; 77():106002. PubMed ID: 31711939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of triple therapy with low-dose total body irradiation and hypo-fractionated radiation plus anti-programmed cell death protein 1 blockade on abscopal antitumor immune responses in breast cancer.
    Liu S; Liao Y; Chen Y; Yang H; Hu Y; Chen Z; Fu S; Wu J
    Int Immunopharmacol; 2023 Apr; 117():110026. PubMed ID: 36934673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
    Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
    J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
    Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
    [No Abstract]   [Full Text] [Related]  

  • 37. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin and Albumin-Based Gold-Cisplatin Nanoparticles Enhance Ablative Radiation Therapy-Induced Antitumor Immunity in Local and Distant Tumor Microenvironment.
    Chen JL; Yang SJ; Pan CK; Lin LC; Tsai CY; Wang CH; Huang YS; Lin YL; Kuo SH; Shieh MJ
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1135-1149. PubMed ID: 36792014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
    Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
    Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.